DelveInsight’s, “Crohn’s Disease Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Crohn’s Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/crohns-disease-pipeline-insight
Key Takeaways from the Crohn’s Disease Pipeline Report
- On April 15, 2026- AbbVie initiated a phase 3 study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn’s Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy.
- On April 13, 2026- Janssen-Cilag Ltd. conducted a phase 3b study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
- On April 13, 2026- Merck Sharp & Dohme LLC initiated a phase 3 Study 1’s primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn’s Disease Activity Index score (<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn’s Disease Activity Index score (<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
- On April 13, 2026- Takeda conducted a phase 2b study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation.
- On April 13, 2026- Janssen Research & Development LLC announced a phase 3 study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn’s Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
- On April 06, 2026- Sanofi conducted a Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease (CD).
- DelveInsight’s Crohn’s Disease pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
- The leading Crohn’s Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.
- Promising Crohn’s Disease Pipeline Therapies such as Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.
Gain in-depth knowledge of key Crohn’s Disease clinical trials, emerging drugs, and market opportunities @ Crohn’s Disease Clinical Trials Assessment
Crohn’s Disease Overview
Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn’s disease has the potential to progress extensively. The inflammation observed in the digestive tract is followed by abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Crohn’s disease in people can be both painful and weakening, sometimes leading to life-threatening complications. The inflammation caused in the intestine can be skipped in between the patches of diseased intestine. The signs and symptoms observed in patients suffering from Crohn’s disease tends to vary and can change over a period of time.
Crohn’s Disease Emerging Drugs Profile
- Guselkumab: Janssen
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. It is currently in Phase III of clinical trial.
- RHB-104: RedHill Biopharma
RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. It is currently in Phase III of clinical trial.
Crohn’s Disease Market Drivers
- Increasing Prevalence of Inflammatory Bowel Disease
- Development of New and Effective Therapies
Crohn’s Disease Market Barriers
- Limited awareness and education
- Failures and discontinuation of emerging therapies
The Crohn’s Disease Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
- Crohn’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market
Uncover critical updates on therapeutic innovations and their potential impact on patients @ Crohn’s Disease Unmet Needs
Crohn’s Disease Companies
Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Crohn’s Disease Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
See the latest progress in drug development and clinical research @ Crohn’s Disease Market Drivers and Barriers, and Future Perspectives
Scope of the Crohn’s Disease Pipeline Report
- Coverage- Global
- Crohn’s Disease Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
- Crohn’s Disease Pipeline Therapies- Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.
- Crohn’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Crohn’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
“Stay Ahead in Gastroenterology Research–Access the Full Crohn’s Disease Pipeline Analysis Today! @ Crohn’s Disease Drugs and Companies
Table of Content
- Introduction
- Crohn’s Disease Executive Summary
- Crohn’s Disease: Overview
- Crohn’s Disease Pipeline Therapeutics
- Crohn’s Disease Therapeutic Assessment
- Crohn’s Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Ozanimod: Bristol-Myers Squibb
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CBP-307: Suzhou Connect Biopharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- IMU-856: Immunic
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Crohn’s Disease Key Companies
- Crohn’s Disease Key Products
- Crohn’s Disease- Unmet Needs
- Crohn’s Disease- Market Drivers and Barriers
- Crohn’s Disease- Future Perspectives and Conclusion
- Crohn’s Disease Analyst Views
- Crohn’s Disease Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/crohns-disease-pipeline-insight